Fintel on MSN16h
HC Wainwright & Co. Upgrades Sarepta Therapeutics (SRPT)
Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...
H.C. Wainwright Sticks to Its Hold Rating for Galectin Therapeutics (GALT)
H.C. Wainwright analyst Ed Arce maintained a Hold rating on Galectin Therapeutics (GALT – Research Report) today. The company’s shares closed ...
Mineralys Therapeutics price target raised to $42 from $30 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Mineralys Therapeutics (MLYS) to $42 from $30 and keeps a Buy rating ...
Kalkine Media19h
Could HC Wainwright's Appraisal Backfire on Cabaletta Bio?
Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...
BiomX (NYSEAMERICAN:PHGE) Stock Price Expected to Rise, HC Wainwright Analyst Says
BiomX (NYSEAMERICAN:PHGE – Free Report) had its price objective boosted by HC Wainwright from $2.00 to $21.00 in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright ...
Kalkine Media21h
Vanda Pharmaceuticals (NASDAQ:VNDA) has been given a Buy rating by HC Wainwright.
Highlights,Vanda Pharmaceuticals posts improved earnings, surpassing market expectations.,Company executives increase stock ...
Explore more
HC Wainwright Reaffirms “Buy” Rating for Genelux (NASDAQ:GNLX)
Genelux (NASDAQ:GNLX – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors ...